BP Aqua Clen 80 (Injection)

BP Aqua Clen 80 is an injectable clenbuterol HCl solution dosed at 80 mcg per millilitre, marketed for subcutaneous use as a fat-loss aid in physique sport. Unlike oral clen tablets (typically 20–40 mcg), the injectable format bypasses first-pass metabolism, which lifts plasma concentration faster but narrows the margin for titration error.

This article covers:

• How BP Aqua Clen 80 differs from oral clenbuterol tablets in route, onset, and precision
• Safe subcutaneous injection technique and a community-convention dosage ladder
• The thermogenic mechanism, fat-loss evidence, and lean-mass-preservation claims
• Cardiovascular and electrolyte side effects specific to injectable use
• South African legal status under SAHPRA Schedule 4 and WADA prohibition
• How to stack BP Aqua Clen 80 with T3, yohimbine, or peptides without compounding risk

Clenbuterol remains a Schedule 4 medicine in South Africa with no human injectable approval.

Last updated: 2026

What Is BP Aqua Clen 80 and How Does It Work?

BP Aqua Clen 80 is an aqueous injectable solution containing 80 mcg of clenbuterol hydrochloride per 1 ml, manufactured by Body Pharm (BP) for subcutaneous administration as a fat-loss aid in physique sport. Clenbuterol itself is a long-acting β2-adrenergic agonist, originally developed as a bronchodilator for asthma and still prescribed orally or by inhalation in some countries for that indication.

The fat-loss mechanism is thermogenic, not anabolic. When clenbuterol binds β2 receptors on adipocytes and skeletal muscle, it activates adenylyl cyclase, raises intracellular cAMP (cyclic adenosine monophosphate), and stimulates lipolysis and heat production. Core body temperature can rise modestly, which lifts resting metabolic rate and daily caloric expenditure for as long as receptors remain responsive. The same β2 activation in bronchial smooth muscle produces the bronchodilation that justifies its medical use.

Clenbuterol is not an anabolic steroid. It does not bind the androgen receptor and does not aromatise to oestrogen. Any lean-mass-sparing effect in a cut comes from β2-mediated changes in protein turnover, not from steroid-like signalling, and the evidence for meaningful muscle gain in humans at fat-loss doses is weak.

The defining feature of BP Aqua Clen 80 versus oral tablets is route and concentration:

• Active ingredient: clenbuterol HCl, identical molecule to oral clen.
• Concentration: 80 mcg per 1 ml aqueous solution.
• Route: subcutaneous injection, bypassing first-pass hepatic metabolism.
• Class: selective β2-adrenergic agonist, not a steroid or SARM (Selective Androgen Receptor Modulator).
• Manufacturer: Body Pharm (BP), sold in South Africa via grey-market retailers.

Stackers commonly pair it with other non-androgenic fat-loss compounds such as BP CYT3 (clenbuterol, yohimbine and T3 combo) or the peptide Body Pharm AOD 9604, though stacking multiplies cardiovascular and thermogenic load.

Medical disclaimer: Clenbuterol is a Schedule 4 medicine in South Africa with no human injectable approval. This article is harm-reduction information for adults who have already decided to research the compound. It is not medical advice, not a prescription, and not an endorsement to use. Consult a registered medical practitioner before using any β2-agonist.

Injectable vs Oral Clenbuterol: Key Differences in 2026

Injectable BP Aqua Clen 80 differs from oral clenbuterol in four practical ways: it bypasses hepatic first-pass metabolism, allows finer dose titration by volume, may reach systemic circulation faster, and adds injection-site risks that oral tablets do not carry. The active molecule (clenbuterol HCl) is identical.

Route and first-pass metabolism

Oral clenbuterol is absorbed through the gut and passes through the liver before reaching systemic circulation. Subcutaneous injection of an aqueous solution bypasses that first pass, which in general pharmacology raises the fraction of an administered dose reaching the bloodstream. Oral clenbuterol is already reported to have high oral bioavailability (roughly 70–80%), so the practical gain from skipping first-pass is likely modest rather than transformative. No 2023–2026 human study directly compares subcutaneous to oral clenbuterol pharmacokinetics.

Dosage precision

At 80 mcg/ml, a 1 ml insulin syringe lets you draw 0.1 ml increments equal to 8 mcg per step. That is finer than splitting a 40 mcg tablet into quarters, which is the usual oral titration ceiling. The product label starting dose is 0.5 ml (40 mcg), matching the typical 20–40 mcg oral starting band consistent with clenbuterol's therapeutic bronchodilator dosing.

Onset

Subcutaneous aqueous solutions typically reach peak plasma faster than oral tablets for small molecules, but this is a pharmacological inference. No peer-reviewed human study of subcutaneous clenbuterol exists as of 2026. Treat any "faster kick-in" claim from grey-market sellers as anecdotal.

Injection-site risk

Oral use has zero injection risk. Subcutaneous use adds bruising, sterile abscess, nodule formation, and infection if technique or sterility is poor. These risks are absent from tablet protocols entirely.

Unverified claim flag: Some sellers and forum posts suggest BP Aqua Clen 80 produces localised fat loss at the injection site (for example, abdominal subcutaneous fat). No peer-reviewed study as of 2026 confirms site-specific fat loss from subcutaneous clenbuterol in humans. Clenbuterol acts systemically via β2 receptors, and subcutaneous injection delivers it to systemic circulation, not selectively to adjacent adipocytes.

Stackers who choose the injectable route often combine it with other injectable fat-loss compounds such as Body Pharm AOD 9604, or run a multi-mechanism stack like BP CYT3. Each added compound multiplies cardiovascular and thermogenic load, so the precision advantage of injectable titration matters more, not less, in a stack.

BP Aqua Clen 80 Dosage Protocol: How to Start Safely

Start at 40 mcg (0.5 ml) subcutaneously once daily, then titrate upward by 20 mcg every 4–7 days only if cardiovascular markers stay within tolerance. The product label specifies 40 mcg as the entry dose, and bodybuilding-community ceilings sit at 120 mcg/day extrapolated from oral bodybuilding protocols. There is no SAHPRA-approved injectable clenbuterol protocol for humans, so the ladder below reflects product-label entry plus community convention, not medical guidance.

Sample titration ladder (community convention, not clinical)

1. Days 1–7: 40 mcg (0.5 ml) SC once daily, morning. Log resting heart rate, blood pressure, and tremor severity daily.
2. Days 8–14: 60 mcg (0.75 ml) SC once daily, only if resting HR stayed under approximately 90 bpm and BP stable on week 1.
3. Days 15–21: 80 mcg (1.0 ml) SC once daily. Most intermediate users plateau here.
4. Optional days 22–28: 100 mcg, escalating to a hard ceiling of 120 mcg/day. Above this, cardiac arrhythmia and hypokalaemia risk rises sharply per documented toxicity cases.
5. Stop point: any chest pain, palpitations exceeding 110 bpm at rest, persistent tremor interfering with sleep, or systolic BP above 150 mmHg. Discontinue and consult a clinician.

Cycling: 2 weeks on, 2 weeks off

Bodybuilders typically run BP Aqua Clen 80 for 14 days, then off for 14 days, to counter β2 receptor downregulation. This is a forum-derived convention, not a clinical schedule, and a 2025 review of clenbuterol abuse describes similar on/off patterns in documented presentations. Ketotifen is sometimes added during the "off" phase to upregulate receptors. This approach is also unverified for this specific use.

Injection technique

Use a 0.5–1.0 ml insulin syringe with a 29–31G, 8–12 mm needle for abdominal or thigh subcutaneous injection. Rotate between left/right abdomen and outer thigh each day to avoid nodule formation. Swab the site with 70% isopropyl alcohol, pinch the skin, inject at 45–90°, and dispose of the sharp in a rigid container.

If you're stacking with BP CYT3 or Body Pharm AOD 9604, reduce the clenbuterol ceiling. The additive cardiovascular load is not linear.

Medical disclaimer: The above reflects product-label information and bodybuilding-community convention. Clenbuterol is a Schedule 4 prescription medicine in South Africa and is not approved by SAHPRA for fat loss. This is not medical advice; consult a registered medical practitioner before use.

Fat Loss and Performance Benefits for Athletes

Clenbuterol injection for fat loss in bodybuilding produces three measurable effects: thermogenesis, lean-mass preservation during a deficit, and bronchodilation that supports harder cardio. None of these are unique to the injectable route. BP Aqua Clen 80 delivers the same molecule with faster onset and no first-pass loss.

Thermogenic fat loss

Clenbuterol raises core temperature and basal metabolic rate, increasing caloric expenditure drawn partly from stored triglycerides. Controlled human trials quantifying the resting-metabolic-rate uplift at fat-loss doses are lacking, so treat any specific percentage figure from sellers as unverified. In practice, a 0.5 ml dose of BP Aqua Clen 80 (40 mcg) is reported to produce a noticeable rise in skin temperature and resting heart rate within 30–45 minutes, which users describe as earlier than the 60–90 minutes commonly reported for oral tablets. These onset figures are anecdotal, not measured in a controlled study.

Lean muscle preservation

The anti-catabolic claim is the most overstated benefit in forum literature. Animal models show clenbuterol increases skeletal muscle mass via β2-adrenoceptor activation, with increased protein accretion and reduced proteolysis, but human data are limited largely to asthma patients and toxicity case series, not resistance-trained athletes in a deficit. A 2025 review documents perceived muscle-sparing as a primary user motivation, but it is observational and does not measure lean mass changes. Treat the muscle-preservation effect as plausible but not proven in humans.

Bronchodilation and training output

Clenbuterol's licensed indication is bronchodilation. Athletes report easier breathing during conditioning work and HIIT (high-intensity interval training) sessions, which can translate into higher training volume during a cut. This is the one benefit with solid mechanistic evidence behind it.

Why "non-steroidal steroid" is a misleading label

Clenbuterol does not bind androgen receptors and has no anabolic steroid mechanism. It will not cause virilising effects (facial hair growth, voice deepening, or clitoral hypertrophy), which is why female competitors at provincial and national level often choose it over oral anabolics. This is also why it pairs well with non-androgenic fat-loss compounds: many users stack BP Aqua Clen 80 with BP CYT3 for layered thermogenesis, or with Body Pharm AOD 9604 for targeted lipolysis without additional cardiovascular load.

Side Effects and Cardiovascular Risks You Must Know

Clenbuterol's adverse event profile is dominated by sympathomimetic and electrolyte effects. Injectable use plausibly intensifies the cardiovascular subset because subcutaneous absorption bypasses first-pass metabolism and can produce a sharper peak plasma concentration than oral dosing. This is a pharmacological inference, not measured in human SC trials.

The documented side effects, drawn from clinical overviews and toxicity case reports, are:

• Tachycardia: the most frequently reported effect, often presenting as a resting heart rate above 100 bpm within 30–60 minutes of dosing.
• Hypertension: systolic spikes are common at doses above 40 mcg/day.
• Hand tremors: fine tremor of the fingers, usually dose-related and worse in the first week before partial tolerance develops.
• Insomnia: driven by the long elimination half-life (roughly 25–39 hours), which is why evening injections are a poor idea.
• Excessive sweating and thermogenic discomfort: expected given the mechanism.
• Hypokalaemia: β2-agonism drives potassium into cells, lowering serum K⁺ and raising the risk of muscle cramps and arrhythmia, with serum potassium as low as 2.2 mEq/L documented in overdose.
• Cardiac arrhythmia and myocardial injury: documented in low-dose toxicity case reports and literature reviews, including troponin elevation in otherwise healthy users.

Why the injectable route may hit harder

Oral clenbuterol has roughly 70–80% bioavailability with a gradual absorption curve. A subcutaneous bolus of BP Aqua Clen 80 likely produces a faster time to maximum plasma concentration (Tmax) and a higher maximum plasma concentration (Cmax) for the same microgram dose, meaning the cardiovascular load arrives sooner and steeper. No 2023–2026 human study has measured this directly, so treat it as a reason to titrate more conservatively, not as a quantified risk.

Red flags that require immediate medical attention

Stop dosing and present to an emergency department if you experience chest pain, palpitations that don't settle within an hour, irregular heartbeat, severe shortness of breath, or fainting. These are not "push through it" symptoms.

Before you inject

Get a baseline ECG (electrocardiogram), resting blood pressure, and serum potassium reading from your GP. Do not stack clenbuterol with ephedrine, high-dose caffeine, or yohimbine-containing pre-workouts without understanding the additive cardiac load. Products like BP CYT3 already bundle the stimulant load, so adding more is reckless. Side effects are dose-dependent and typically resolve within days of cessation.

Clenbuterol Legal Status in South Africa (2026)

Clenbuterol is a Schedule 4 prescription-only medicine in South Africa under the Medicines and Related Substances Act 101 of 1965, regulated by SAHPRA. It has no SAHPRA-registered indication for fat loss, bodybuilding, or athletic performance. Its only recognised use is a narrow bronchodilator application in veterinary and (historically) human respiratory contexts.

Possessing or supplying clenbuterol without a valid prescription is an offence under the Act. BP Aqua Clen 80 is not a SAHPRA-registered human medicine, which places it outside the legal supply chain regardless of intent.

What this means in practice for SA buyers and athletes

1. Prescription requirement: legal personal possession requires a script from a registered medical practitioner for a recognised indication. Fat loss is not one.
2. WADA Prohibited List 2026: clenbuterol remains prohibited at all times under class S1: Anabolic Agents, in- and out-of-competition with no urinary threshold. Any detectable amount is an adverse analytical finding.
3. SA testing bodies affected: athletes under SAIDS (South African Institute for Drug-Free Sport), Athletics South Africa, SA Rugby, Netball SA, Cricket SA and any SASCOC (South African Sports Confederation and Olympic Committee)-affiliated federation are subject to this rule.
4. Contaminated meat defence is narrow: WADA acknowledges clenbuterol contamination in meat from some countries, but the burden of proof sits on the athlete and sanctions are still common. South African meat supply has no documented clenbuterol contamination signal in 2023–2026.
5. Customs and import risk: Schedule 4 substances imported without authorisation can be seized by SARS (South African Revenue Service) Customs, with possible criminal referral.

Disclaimer

BeSkinny does not provide legal or medical advice. The information on this page, including the BP CYT3 clenbuterol, yohimbine and T3 combo reference and the Body Pharm AOD 9604 stacking note, is educational. Compliance with South African law and any applicable anti-doping code is the reader's responsibility. We will not advise on circumventing SAHPRA, SARS, or SAIDS processes.

How BP Aqua Clen 80 Fits Into a Fat-Loss Stack

Most South African users don't run BP Aqua Clen 80 in isolation. The standard fat-loss stack pairs clenbuterol with T3 (liothyronine) for thyroid-driven metabolic uplift and yohimbine HCl for α2-adrenergic blockade in stubborn fat depots. The pharmacological logic is straightforward: clenbuterol drives β2 lipolysis, T3 raises basal metabolic rate, and yohimbine removes the α2 brake that protects lower-body and lower-abdominal fat. Each compound also amplifies the others' cardiovascular load, which is the trade-off.

If you want all three in a single pre-mixed product rather than dosing them separately, the BP CYT3 (Clenbuterol, Yohimbine and T3 combo) is the in-house option. Running the combo means you lose the ability to titrate each component independently, which matters if you're new to T3 or sensitive to yohimbine-induced anxiety.

Peptide layering is the other common direction. Body Pharm AOD 9604, a synthetic fragment of the C-terminus of human growth hormone, is marketed for fat loss without the IGF-1 (insulin-like growth factor 1) elevation of full GH analogues. Evidence in humans is limited and its largest obesity trial did not meet its primary endpoint, so treat the fat-loss claim as unproven rather than established.

A different route entirely is GLP-1 (glucagon-like peptide-1) agonism. Semaglutide works through appetite suppression and delayed gastric emptying, not thermogenesis, and carries a published clinical evidence base that clenbuterol lacks. It's worth considering if your goal is sustained caloric deficit under medical supervision rather than a short cutting block.

Two cautions before stacking:

1. Cardiovascular load compounds: Clen plus T3 plus yohimbine simultaneously raises heart rate, contractility, and sympathetic tone. Resting tachycardia above 100 bpm is a stop signal.
2. Side-effect attribution becomes impossible: If tremor, insomnia, or palpitations appear on a three-compound stack, you cannot isolate the culprit without unwinding the stack one item at a time.

Frequently Asked Questions

Can women use BP Aqua Clen 80?

Yes, women can use BP Aqua Clen 80, typically at lower starting doses than men. A common starting point is 20 mcg (0.25 ml) subcutaneously, titrated by 20 mcg every few days to a ceiling around 80–100 mcg daily. Clenbuterol is not androgenic, so virilisation is not a concern, but tachycardia and tremor scale with body mass.

How long does a clenbuterol cycle last?

Typical clenbuterol cycles run two weeks on, two weeks off, or alternate-day dosing across a six-week block. These conventions come from coach consensus and underground guides, not controlled trials. β2-receptor downregulation drives the on/off structure, with some users adding ketotifen at night to extend receptor sensitivity.

Does clenbuterol cause muscle loss?

Clenbuterol is anti-catabolic in animal models but human muscle-sparing data are weak. In a sustained caloric deficit, lean mass loss still occurs; clen may attenuate it rather than prevent it. Pair the cycle with adequate protein (1.8–2.2 g/kg) and resistance training to protect lean mass.

How do I prepare the injection?

BP Aqua Clen 80 ships as a pre-mixed aqueous solution at 80 mcg/ml, so no reconstitution is required. Draw the target volume with a 29–31G insulin syringe (0.5 or 1 ml), swab the abdominal SC site with alcohol, pinch the skin, and inject at 45–90°.

Is clenbuterol detectable in drug tests?

Clenbuterol is prohibited at all times under WADA's 2026 Prohibited List, Class S1 Anabolic Agents, with no threshold concentration. Detection windows in urine extend several days to weeks depending on dose and duration. Any detected amount is treated as an adverse analytical finding unless contamination can be established under WADA's framework.

What is the difference between BP Aqua Clen 80 and oral clenbuterol tablets?

BP Aqua Clen 80 is an 80 mcg/ml aqueous solution injected subcutaneously; oral clenbuterol is a tablet swallowed and absorbed via the gut at roughly 70–80% bioavailability. No 2023–2026 human PK study directly compares SC to oral routes, so claims of superior potency per microgram for the injectable are unverified.

Key Takeaways

• BP Aqua Clen 80 is a Schedule 4 prescription-only medicine in South Africa with no SAHPRA approval for fat loss; possession without a valid script is illegal.
• The injectable format bypasses first-pass metabolism, allowing finer titration by volume (8 mcg per 0.1 ml step) but adding injection-site risks absent from oral tablets.
• Start at 40 mcg (0.5 ml) subcutaneously once daily and titrate by 20 mcg every 4–7 days, with a community ceiling of 120 mcg/day; stop immediately if chest pain, palpitations, or systolic BP above 150 mmHg occurs.
• Thermogenic fat loss is the primary mechanism; lean-mass preservation is plausible but unproven in humans, and bronchodilation is the one benefit with solid mechanistic evidence.
• Cardiovascular side effects (tachycardia, hypertension, arrhythmia) and hypokalaemia are the main risks; injectable use may produce a sharper peak plasma concentration than oral dosing, so conservative titration is prudent.
• Clenbuterol is WADA-prohibited with no threshold; any detectable amount is an adverse analytical finding for athletes under SAIDS, Athletics South Africa, SA Rugby, Netball SA, Cricket SA, or SASCOC-affiliated bodies.
• Stacking with T3 and yohimbine (or the pre-mixed BP CYT3) multiplies cardiovascular load; do not add ephedrine, high-dose caffeine, or additional stimulants without baseline ECG and potassium testing.

Next Steps

Before using BP Aqua Clen 80, obtain a baseline ECG, resting blood pressure reading, and serum potassium test from your GP. If you proceed, start at 40 mcg (0.5 ml) subcutaneously once daily, log your resting heart rate and blood pressure daily, and titrate conservatively by 20 mcg every 4–7 days only if cardiovascular markers remain stable. If you're stacking with other compounds, reduce the clenbuterol ceiling and monitor for side-effect attribution. If chest pain, palpitations, or irregular heartbeat occur, stop immediately and seek emergency care. For legal and anti-doping compliance, consult a registered medical practitioner or sports medicine specialist before use.

References

1. Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences. Cureus, 2025.
2. Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. Journal of Pharmacobio-Dynamics, 1985.
3. Low Dose Clenbuterol Toxicity: Case Report and Review of Literature. HCA Healthcare Journal of Medicine, 2020.
4. Anabolic effects of clenbuterol on skeletal muscle are mediated by beta-2 adrenoceptor activation. American Journal of Physiology, 1992.
5. Medicines and Related Substances Act 101 of 1965 (as amended). South African Health Products Regulatory Authority (SAHPRA), 1965.
6. The Prohibited List (2026). World Anti-Doping Agency, 2026.
7. Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone. Hormone Research, 2000.
8. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021.